Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars - PDF (俄语)

Address of the Editorial Office:

• Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

• Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

• Tel.: +7 (926) 905-41-26
• E-mail: e.gorbacheva@ter-arkhiv.ru